Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

March 5, 2020 by Alan Khadavi

Asthma biologic agents (Xolair, Cinqair, Nucala, Fasenra, Dupixent)

The last several years have seen an influx of asthma biologic agents to hit the market. Here we will discuss the 5 that are currently FDA approved to treat type 2 inflammatory asthma. Type 2 asthma inflammation is triggered by IL-4, IL-5, and IL-13 along with other inflammatory mediators. Half of all patients with asthma have evidence of Type 2 inflammation. Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels and airway gene expression markers are frequently used biomarkers to diagnose Type 2 asthma. Individuals tend to have several features of increased asthma severity including reduced lung function and increased rates of asthma exacerbations and Type 2 high patients show airway remodeling and alterations in mucus production.  Several monoclonal antibodies are now available to treat these patients and reduce asthma exacerbation rates.

  1. Xolair (Omalizumab)
  • targets IgE
  • Biomarker is Total IgE 30-700 kU/L (>12 years) or 30-1300 kU/L (6-11 years of age)
  • Originally approved in 2003; now approved for 6 years of age and up
  • Administered subcutaneously every 2-4 weeks, dose based on IgE level and weight
  • clinical outcomes are reduced exacerbations and oral steroid use

2. Cinqair (Reslizumab)

  • Anti-IL-5
  • Biomarker is blood eosinophil >400/uL
  • Approved in 2016 for 18 years and up
  • Administered as an IV infusion 3mg/kg every 4 weeks
  • clinical outcome is reduced exacerbations, especially with rhinosinusitis with nasal polyps.

3. Nucala (Mepolizumab)

  • Anti-IL-5
  • Biomarker is blood eosinophil >150/uL
  • Approved in 2015 for 12 years and up, and now approved for 6 years and up.
  • Administered 40 mg (6-11 years old) or 100 mg (12 years and up), subcutaneously every 4 weeks.
  • outcomes are reduced exacerbations and improved quality of life and lung function.

4. Fasenra (Benralizumab)

  • Anti-IL-5R a
  • Biomarker is blood eosinophil >150/uL
  • Approved in 2017 for 12 and up
  • 30mg SQ every 4 weeks X 3, then every 8 weeks
  • outcomes are reduced exacerbations and improved lung function

5.  Dupixent (Dupilumab)

  • Anti-IL-4ra
  • Biomarker is blood eosinophil >150/uL
  • Approved in 2017 for 12 and up
  • 400 or 600 mg loading dose, then 200 or 300 mg SQ every 2 weeks
  • outcomes are reduced exacerbations and improved quality of life and lung function

These are the current asthma biologic agents available. Type 2 asthma is the most established form of asthma characterized by severe exacerbations and reduced lung function. Blood eosinophil counts are the most established biomarker to establish disease currently.

Nucala vs. Fasenra vs. Cinqair; A Comparison Study

Nucala (mepolizumab) vs. Cinqair (reslizumab)

Costs of Asthma Biologic Medications

Allergy Biologics, Past, Present and Future…

Asthma Biologics, what is their role in asthma?

 

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page